Amanta Healthcare IPO

Founded in 1994, Amanta Healthcare operates as a specialized pharmaceutical manufacturing company focused on sterile liquid formulations. The organization serves diverse therapeutic areas including fluid therapy solutions, respiratory medications, ophthalmic products, medical diluents, and irrigation formulations.

Amanta Healthcare IPO

Pharmaceutical Formulation Manufacturer

LIVE IPO
IPO Date
01st – 03rd Sep 2025
Listing Date
09 Sep 2025
Price Range
₹120 – ₹126
Lot Size
119 shares
₹14,994 (Retail)
Issue Size
₹126 Crores
📅 IPO Schedule
Event Date
Issue Open Date01 Sep 2025
Issue Close Date03 Sep 2025
UPI Mandate Deadline03 Sep 2025 (5 PM)
Allotment Finalization04 Sep 2025
Refund Initiation08 Sep 2025
Share Credit08 Sep 2025
Listing Date09 Sep 2025
Mandate End Date18 Sep 2025
🏢 About Amanta Healthcare

Founded in 1994, Amanta Healthcare operates as a specialized pharmaceutical manufacturing company focused on sterile liquid formulations. The organization serves diverse therapeutic areas including fluid therapy solutions, respiratory medications, ophthalmic products, medical diluents, and irrigation formulations.

The company’s production facility spans over 66,000 square meters in Hariyala, Kheda district, Gujarat. This state-of-the-art manufacturing unit features advanced LVP (Large Volume Parenteral) and SVP (Small Volume Parenteral) production lines utilizing ABFS (Aseptic Blow Fill Seal) and ISBM (Injection Stretch Blow Molding) technologies. The facility maintains WHO-GMP compliance and has earned multiple quality certifications including ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018.

💰 Financial Details

Issue Size Breakdown

Overall Issue ₹126 Crores
Fresh Issue ₹126 Crores

Fund Utilization

New SteriPort Production Line Setup
₹70 Cr (55.5%)
SVP Manufacturing Line Development
₹30.13 Cr (24%)
Corporate Operations & Working Capital
₹25.87 Cr (20.5%)
💪 Company Strengths
  • Nearly three decades of operational experience since 1994 with a broad pharmaceutical product range
  • Sophisticated sterile liquid production capabilities spanning various volume specifications
  • Quality-assured manufacturing facility with international certifications and cutting-edge technology
  • Well-established distribution channels covering both domestic and international markets
  • Strong management team supported by a competent and qualified workforce
⚠️ Risk Factors
  • Significant reliance on key customers creates potential revenue volatility and business dependency concerns
  • Potential delays in SteriPort and SVP facility expansion could hinder projected growth objectives
  • Personal guarantees by promoters on company loans may create operational constraints
  • Manufacturing sterile liquid pharmaceuticals involves substantial product liability risks
  • Dependence on unsecured loans and personal guarantees may increase overall financial risk exposure
📊 Subscription Status

Application statistics recorded at 5:00 PM on September 01, 2025:

Category Reserved (Lakhs) Applied (Lakhs) Subscription
Institutional 20.00 0.78 0.04x
NII 15.00 87.33 5.82x
Retail 35.00 235.04 6.72x
Total 70.00 323.16 4.62x
Posted in IPO

Leave a Reply

Your email address will not be published. Required fields are marked *